Dergiler / Turkish Journal of Obstetrics and Gynecology / 2021 / Cilt: 18 - Sayı: 3

The combined effect of anti-D and non-D Rh antibodies in maternal alloimmunization

Maternal alloimmünizasyonda anti-D ve D dışı Rh antikorlarının kombine etkisi

Sayfa
181–189
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Also, anti-D in association with non-D Rh antibodies resulted in more severe HDFN requiring more invasive treatment procedures, including IUT, neonatal exchange transfusion, or top-up transfusion.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: This study aims to investigate the distribution of antibodies that cause hemolytic disease of the fetus and newborn (HDFN) and compare the clinical outcomes of pregnancies affected by anti-D and anti-D combined with non-D Rh alloimmunization.
📊
Temel Bulgular & Veri:Materials and Methods: We retrospectively searched and obtained the perinatal and neonatal data of patients with anti-D antibodies and anti-D combined with non-D Rh antibodies (anti-c, -C, -e, -E, and -Kell) from October 2015 to December 2018 at the University of Health Sciences Turkey, Kanuni Sultan Süleyman Training and Research Hospital.
💡
Sonuç & Katkı:Also, anti-D in association with non-D Rh antibodies resulted in more severe HDFN requiring more invasive treatment procedures, including IUT, neonatal exchange transfusion, or top-up transfusion.
🔬Tür:Araştırma Makalesi
📍Kapsam:2015 Verileri
⚙️Değişkenler:Alan Parametreleri

Özet

Objective: This study aims to investigate the distribution of antibodies that cause hemolytic disease of the fetus and newborn (HDFN) and compare the clinical outcomes of pregnancies affected by anti-D and anti-D combined with non-D Rh alloimmunization. Materials and Methods: We retrospectively searched and obtained the perinatal and neonatal data of patients with anti-D antibodies and anti-D combined with non-D Rh antibodies (anti-c, -C, -e, -E, and -Kell) from October 2015 to December 2018 at the University of Health Sciences Turkey, Kanuni Sultan Süleyman Training and Research Hospital. Univariate and multiple logistic regression analyses and adjusted odds ratios with their confidence intervals were used to define independent risk factors for non-D antibody positive. Results: The severe fetal hydrops rate was significantly higher in the anti-D combined non-D group (3/25, 12%) than in the anti-D group (1/128, 0.08%, p<0.001). The intrauterine transfusion (IUT) requirement in the anti-D combined non-D group (16/25, 64%) tended to be significantly higher than that in the anti-D group (5/128, 7.46%, p<0.001). The incidence of neonatal exchange transfusion, top-up transfusion, and postnatal phototherapy frequency in the anti-D combined non-D group was significantly higher than in the anti-D group. Conclusion: Anti-D combined with another non-D Rh alloantibody resulted in significantly higher HDFN rates than the anti-D alloimmunized pregnancies. Also, anti-D in association with non-D Rh antibodies resulted in more severe HDFN requiring more invasive treatment procedures, including IUT, neonatal exchange transfusion, or top-up transfusion.

Abstract

Amaç: Bu çalışma, fetüs ve yenidoğanın hemolitik hastalığına (FYHH) neden olan antikorların dağılımını araştırmayı ve anti-D ile birlikte D dışı Rh antikorlardan etkilenen gebeliklerin klinik sonuçlarını anti-D tarafından etkilenen gebeliklerle karşılaştırmayı amaçlamaktadır. Gereç ve Yöntemler: Sağlık Bilimleri Üniversitesi Kanuni Sultan Süleyman Eğitim ve Araştırma Hastanesi’nde Ekim 2015 - Aralık 2018 tarihleri arasında anti-D antikorları ve anti-D ile kombine D dışı (anti-c, -C, -e, -E, ve -Kell) Rh antikorları olan hastaların perinatal ve neonatal sonuçlarını geriye dönük olarak araştırdık. D dışı antikor pozitifliğinin varlığı için bağımsız risk faktörlerini tanımlamak için, tek değişkenli ve çoklu lojistik regresyon analizleri ve bunların güven aralıklarıyla ayarlanmış olasılık oranlarını kullandık. Bulgular: Şiddetli fetal hidrops oranı anti-D ile kombine D dışı grupta (3/25, %12) anti-D grubundan (1/128, %0,08) anlamlı olarak daha yüksekti (p<0,001). Anti-D ile kombine D dışı gruptaki (16/25, %64) intrauterine transfüzyon (İUT) gereksinimi anti-D grubundan (5/128, %7,46) önemli ölçüde daha yüksekti (p<0,001). Anti-D ile kombine D dışı grupta neonatal kan değişimi, tamamlayıcı transfüzyon ve postnatal fototerapi sıklığı anti-D grubuna göre anlamlı olarak daha yüksekti. Sonuç: Anti-D ile kombine D-dışı Rh alloantikoru ile oluşan gebelikler anti-D alloimmünize gebeliklerden önemli ölçüde daha yüksek FYHH oranları ile sonuçlanmıştır. Ayrıca, D-dışı Rh antikorları ile birlikte anti-D antikor varlığı, İUT, neonatal kan değişimi ve tamamlayıcı transfüzyon da dahil olmak üzere invaziv prosedürleri gerektiren daha ciddi FYHH ile sonuçlandı

🔖

Bu Makaleye Atıf Yap

ÖZKÖSE, Z. G., OĞLAK, S. C. (2021). The combined effect of anti-D and non-D Rh antibodies in maternal alloimmunization. Turkish Journal of Obstetrics and Gynecology, Cilt: 18 - Sayı: 3, 181–189. https://ajindex.com/articles/376437

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

  1. Raashid Y, Ali A, Ehsan Y, Jafri H, Waheed I, Mason G, et al. Intrauterine Fetal Blood Transfusion (IUBT) for Rh Incompatibility - 12 Years’ Experience from Pakistan. J Coll Physicians Surg Pak 2020;30:1193-6
  2. Sahoo T, Sahoo M, Gulla KM, Gupta M. Rh alloimmunisation: current updates in antenatal and postnatal Management. Indian J Pediatr 2020;87:1018-28
  3. ACOG Practice Bulletin No. 192: management of alloimmunization during pregnancy. Obstet Gynecol 2018;131:e82-90. doi: 10.1097/ AOG.0000000000002528
  4. Zipursky A, Paul VK. The global burden of Rh disease. Arch Dis Child Fetal Neonatal Ed 2011;96:F84-5. doi: 10.1136/adc.2009.181172. 5. de Haas M, Thurik FF, Koelewijn JM, van der Schoot CE. Haemolytic disease of the fetus and newborn. Vox Sang 2015;109:99-113
  5. Fung KFK, Eason E. No. 133-prevention of Rh alloimmunization. J Obstet Gynaecol Can 2018;40:e1-10. doi: 10.1016/j. jogc.2017.11.007
  6. Zwiers C, Koelewijn JM, Vermij L, van Sambeeck J, Oepkes D, de Haas M, et al. ABO incompatibility and RhIG immunoprophylaxis protect against non-D alloimmunization by pregnancy. Transfusion 2018;58:1611-7
  7. Healsmith S, Savoia H, Kane SC. How clinically important are non-D Rh antibodies? Acta Obstet Gynecol Scand 2019;98:877-84
  8. Koelewijn JM, Vrijkotte TG, de Haas M, van der Schoot CE, Bonsel GJ. Risk factors for the presence of non-rhesus D red blood cell antibodies in pregnancy. BJOG 2009;116:655-64
  9. Phung TV, Houfflin-Debarge V, Ramdane N, Ghesquière L, Delsalle A, Coulon C, et al. Maternal red blood cell alloimmunization requiring intrauterine transfusion: a comparative study on management and outcome depending on the type of antibody. Transfusion 2018;58:1199-205
  10. Lieberman L, Callum J, Cohen R, Cserti-Gazdewich C, Ladhani NNN, Buckstein J, et al. Impact of red blood cell alloimmunization on fetal and neonatal outcomes: A single center cohort study. Transfusion 2020;60:2537-46
  11. Farrell M, Clarke G, Barr G, Hannon J. Monitoring of prenatal patients using a combined antibody titre for Rh and non-Rh antibodies. Transfus Med 2020;30:210-4
  12. Zwiers C, Oepkes D, Lopriore E, Klumper FJ, de Haas M, van Kamp IL. The near disappearance of fetal hydrops in relation to current state-of-the-art management of red cell alloimmunization. Prenat Diagn 2018;38:943-50
  13. Mari G, Adrignolo A, Abuhamad AZ, Pirhonen J, Jones DC, Ludomirsky A, et al. Diagnosis of fetal anemia with Doppler ultrasound in the pregnancy complicated by maternal blood group